This book brings advances in genetics, neurobiology, and psychopharmacology to the clinic to enhance treatment for neurodevelopmental disorders. Significant progress has been made in identifying the neurobiological mechanisms of several disorders and targeted treatments are modifying the outcome of these disorders.
This book brings advances in genetics, neurobiology, and psychopharmacology to the clinic to enhance treatment for neurodevelopmental disorders. Significant progress has been made in identifying the neurobiological mechanisms of several disorders and targeted treatments are modifying the outcome of these disorders.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Randi Hagerman is an expert in the treatment in neurodevelopmental disorders with expertise in targeted treatments that reverse the neurobiological abnormalities associated with a specific disorder. This new age of targeted treatments has led to new interventions which are changing the trajectories of development for many of these children. Dr. Robert Hendren is a psychiatrist who focuses on the diagnosis and treatment of neurodevelopmental disorders including autism. His research has spanned a variety of illnesses, from autism, schizophrenia and bipolar disorder to eating and impulse control disorders. In 2001 he became diretor of the MIND Institute at the University of California, Davis. where he developed a strong clinical trials program that has tested many new treatments for autism. Since 2009 as director of child and adolescent psychiatry at UCSF.
Inhaltsangabe
* Foreword * PrefaceContributors * 1: Robert Hendren, Andre Goldani, and Randi Hagerman: Overview of Neurodevelopmental Processes and the Assessment of Patients with Neurodevelopmental Disorders * 2: Robert Hendren and Randi Hagerman: Autism: Neurobiological Mechanisms and Targeted Treatments * 3: Danielle Schlosser, Coleman Garrett, and Sophia Vinogradov: Targeted Treatments in Schizophrenia * 4: Blake Rawdin, Daniel Lindqvist, Nicole Bush, Steven Hamilton, Ruhel Bopari, R. Scott Mackin, Victor Reus, Synthia Mellon, and Owen Wolkowitz: Neurodevelopmental and Neurobiological Aspects of Major Depressive Disorder: From Theory to Therapy * 5: Kyle Rutledge, Kyhati Brahmbhatt, and Julie Schweitzer: Attention-Deficit Hyperactivity Disorder * 6: Daniel Tarquinio and Walter Kaufmann: Targeted Treatments in Rett Syndrome * 7: William Tidyman and Katherine Rauen: Cardio-Facio-Cutaneous Syndrome and Other RASopathies: Prospects for Treatment * 8: Petrus de Vries: Targeted Treatments in Tuberous Sclerosis Complex (TSC) * 9: Reymundo Lozano, Emma Hare, and Randi Hagerman: Treatment of Fragile X Syndrome and Fragile X-associated Disorders * 10: Mary Leigh, Lindsey Partington, and Edwin Weeber: Angelman Syndrome * 11: Aarti Ruparelia. David Patterson, and William Mobley: Pharmacotherapy for Cognitive Enhancement in Down Syndrome * 12: Billur Moghaddam: Targeted Treatments for Phenylketonuria * 13: Bethany Lipa, Que Nguyen, and Jay Han: Muscular Dystrophies: Diagnosis and New Treatments * 14: Randi Hagerman, Billur Moghaddam, Jan Nolta, Maria Diez-Juan, and Robert Hendren: Translating Treatments from the Laboratory to the Clinic * Index
* Foreword * PrefaceContributors * 1: Robert Hendren, Andre Goldani, and Randi Hagerman: Overview of Neurodevelopmental Processes and the Assessment of Patients with Neurodevelopmental Disorders * 2: Robert Hendren and Randi Hagerman: Autism: Neurobiological Mechanisms and Targeted Treatments * 3: Danielle Schlosser, Coleman Garrett, and Sophia Vinogradov: Targeted Treatments in Schizophrenia * 4: Blake Rawdin, Daniel Lindqvist, Nicole Bush, Steven Hamilton, Ruhel Bopari, R. Scott Mackin, Victor Reus, Synthia Mellon, and Owen Wolkowitz: Neurodevelopmental and Neurobiological Aspects of Major Depressive Disorder: From Theory to Therapy * 5: Kyle Rutledge, Kyhati Brahmbhatt, and Julie Schweitzer: Attention-Deficit Hyperactivity Disorder * 6: Daniel Tarquinio and Walter Kaufmann: Targeted Treatments in Rett Syndrome * 7: William Tidyman and Katherine Rauen: Cardio-Facio-Cutaneous Syndrome and Other RASopathies: Prospects for Treatment * 8: Petrus de Vries: Targeted Treatments in Tuberous Sclerosis Complex (TSC) * 9: Reymundo Lozano, Emma Hare, and Randi Hagerman: Treatment of Fragile X Syndrome and Fragile X-associated Disorders * 10: Mary Leigh, Lindsey Partington, and Edwin Weeber: Angelman Syndrome * 11: Aarti Ruparelia. David Patterson, and William Mobley: Pharmacotherapy for Cognitive Enhancement in Down Syndrome * 12: Billur Moghaddam: Targeted Treatments for Phenylketonuria * 13: Bethany Lipa, Que Nguyen, and Jay Han: Muscular Dystrophies: Diagnosis and New Treatments * 14: Randi Hagerman, Billur Moghaddam, Jan Nolta, Maria Diez-Juan, and Robert Hendren: Translating Treatments from the Laboratory to the Clinic * Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
